Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3

Watchlist Manager
Hapvida Participacoes e Investimentos SA Logo
Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3
Watchlist
Price: 35.77 BRL -5.52% Market Closed
Market Cap: 17.8B BRL
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

The Relative Value of one HAPV3 stock under the Base Case scenario is 101.8 BRL. Compared to the current market price of 35.77 BRL, Hapvida Participacoes e Investimentos SA is Undervalued by 65%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

HAPV3 Relative Value
Base Case
101.8 BRL
Undervaluation 65%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

1
P/S
P/S
Price to Sales
1
vs History
69
vs Industry
76
Median 3Y
1.1
Median 5Y
2
Industry
2.2
Forward
0.5
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-41
Median 5Y
-25.5
Industry
21.7
Forward
167.6
More Details
6.6
P/OCF
P/OCF
Price to OCF
6.6
vs History
90
vs Industry
45
Median 3Y
13.9
Median 5Y
37.9
Industry
13.9
More Details
21.3
P/FCFE
P/FCFE
Price to FCFE
21.3
vs History
46
vs Industry
18
Median 3Y
21.9
Median 5Y
20.2
Industry
19.7
More Details
0.4
P/B
P/B
Price to Book Value
0.4
vs History
90
vs Industry
80
Median 3Y
0.6
Median 5Y
0.7
Industry
2.1
More Details
1.4
EV/S
EV/S
Enterprise Value to Sales
1.4
vs History
66
vs Industry
72
Median 3Y
1.4
Median 5Y
2.4
Industry
2.3
Forward
0.7
More Details
6.4
EV/GP
EV/GP
Enterprise Value to Gross Profit
6.4
vs History
71
vs Industry
32
Median 3Y
6.9
Median 5Y
11.5
Industry
4.8
More Details
6.9
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
6.9
vs History
92
vs Industry
42
Median 3Y
12.2
Median 5Y
20.6
Industry
11.4
Forward
5.4
More Details
13.2
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13.2
vs History
95
vs Industry
30
Median 3Y
55.6
Median 5Y
46
Industry
15.4
Forward
11.4
More Details
8.6
EV/OCF
EV/OCF
Enterprise Value to OCF
8.6
vs History
92
vs Industry
41
Median 3Y
17.5
Median 5Y
40.1
Industry
13.7
More Details
12.9
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
12.9
vs History
65
vs Industry
31
Median 3Y
16.3
Median 5Y
17.3
Industry
17.2
More Details
0.4
EV/IC
EV/IC
Enterprise Value to IC
0.4
vs History
92
vs Industry
81
Median 3Y
0.5
Median 5Y
0.6
Industry
1.8
More Details

Multiples Across Competitors

HAPV3 Competitors Multiples
Hapvida Participacoes e Investimentos SA Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
BR
Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3
17.7B BRL 1 -33.5 6.9 13.2
US
UnitedHealth Group Inc
NYSE:UNH
276.3B USD 0.7 12.5 8.3 9.4
US
Anthem Inc
LSE:0HG8
96.6B USD 0.5 16.3 11.2 13
US
Elevance Health Inc
NYSE:ELV
84.4B USD 0.5 14.3 10.1 11.7
US
Humana Inc
NYSE:HUM
28.8B USD 0.2 16.8 8.2 10.3
US
Centene Corp
NYSE:CNC
26.6B USD 0.2 7.7 5.7 7.6
US
Molina Healthcare Inc
NYSE:MOH
15.9B USD 0.4 13.5 5.4 6
US
Healthequity Inc
NASDAQ:HQY
9B USD 7.3 74 24.1 40.2
US
Magellan Health Inc
F:MAH1
2.2B EUR 0.5 8.5 13 38.6
US
Progyny Inc
NASDAQ:PGNY
1.8B USD 1.5 34.1 20 21
US
Clover Health Investments Corp
NASDAQ:CLOV
1.4B USD 0.9 -55.3 -53.6 -50.4
P/E Multiple
Earnings Growth PEG
BR
Hapvida Participacoes e Investimentos SA
BOVESPA:HAPV3
Average P/E: 22
Negative Multiple: -33.5 		N/A N/A
US
UnitedHealth Group Inc
NYSE:UNH
12.5
24%
0.5
US
A
Anthem Inc
LSE:0HG8
16.3
20%
0.8
US
Elevance Health Inc
NYSE:ELV
14.3
20%
0.7
US
Humana Inc
NYSE:HUM
16.8
30%
0.6
US
Centene Corp
NYSE:CNC
7.7
11%
0.7
US
Molina Healthcare Inc
NYSE:MOH
13.5
15%
0.9
US
Healthequity Inc
NASDAQ:HQY
74
67%
1.1
US
M
Magellan Health Inc
F:MAH1
8.5
N/A N/A
US
Progyny Inc
NASDAQ:PGNY
34.1
20%
1.7
US
Clover Health Investments Corp
NASDAQ:CLOV
Negative Multiple: -55.3 N/A N/A

See Also

Summary
HAPV3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
HAPV3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
HAPV3 stock valuation using valuation multiples.
Wall Street Estimates
HAPV3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
HAPV3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 263,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.